INmune Bio Inc Sustainability Reports
INmune Bio, Inc. is a clinical-stage immunology company that focuses on developing drug therapies designed to reprogram a patient's innate immune system. Its development pipeline includes treatments targeting cancer, neuroinflammation, and Alzheimer's disease.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
FIGI: BBG00LW94M14
2 reports from 2018 to 2019
Company Profile
INmune Bio, Inc. is a clinical-stage immunology company that focuses on developing drug therapies designed to reprogram a patient's innate immune system. Its development pipeline includes treatments targeting cancer, neuroinflammation, and Alzheimer's disease.
Reports
2 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
